Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome
Ovarian hyperstimulation syndrome (OHSS) is a complication of ovarian stimulation with gonadotropins followed by the administration of human chorionic gonadotropin (hCG) to trigger the final steps of oocyte maturation. Gonadotropin-releasing hormone (GnRH) analogs are thought to be effective in prev...
Guardado en:
Autores principales: | , , , |
---|---|
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03037207_v335_n2_p116_Scotti http://hdl.handle.net/20.500.12110/paper_03037207_v335_n2_p116_Scotti |
Aporte de: |
id |
paper:paper_03037207_v335_n2_p116_Scotti |
---|---|
record_format |
dspace |
institution |
Universidad de Buenos Aires |
institution_str |
I-28 |
repository_str |
R-134 |
collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
topic |
Angiogenesis GnRH-I agonist Luteolysis OHSS Ovary alpha smooth muscle actin angiopoietin 1 angiopoietin 2 angiopoietin receptor cholesterol monooxygenase (side chain cleaving) chorionic gonadotropin cycline estradiol leuprorelin progesterone seric gonadotropin steroidogenic acute regulatory protein vasculotropin vasculotropin receptor 2 angiogenesis animal cell animal experiment animal model animal tissue apoptosis article blood vessel parameters cell proliferation controlled study corpus luteum down regulation drug efficacy drug mechanism estradiol blood level female gonadotropin blood level histopathology in vivo study luteal cell nonhuman ovary development ovary hyperstimulation peritoneal fluid level priority journal progesterone blood level protein analysis protein expression protein localization rat steroidogenesis vascular endothelium vascular stability Angiopoietin-1 Angiopoietin-2 Animals Apoptosis Blood Vessels Cell Proliferation Cholesterol Side-Chain Cleavage Enzyme Corpus Luteum Female Fertility Agents, Female Gonadal Steroid Hormones Gonadotropins, Equine Leuprolide Ovarian Hyperstimulation Syndrome Ovary Phosphoproteins Rats Rats, Sprague-Dawley Receptor, TIE-2 Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-2 |
spellingShingle |
Angiogenesis GnRH-I agonist Luteolysis OHSS Ovary alpha smooth muscle actin angiopoietin 1 angiopoietin 2 angiopoietin receptor cholesterol monooxygenase (side chain cleaving) chorionic gonadotropin cycline estradiol leuprorelin progesterone seric gonadotropin steroidogenic acute regulatory protein vasculotropin vasculotropin receptor 2 angiogenesis animal cell animal experiment animal model animal tissue apoptosis article blood vessel parameters cell proliferation controlled study corpus luteum down regulation drug efficacy drug mechanism estradiol blood level female gonadotropin blood level histopathology in vivo study luteal cell nonhuman ovary development ovary hyperstimulation peritoneal fluid level priority journal progesterone blood level protein analysis protein expression protein localization rat steroidogenesis vascular endothelium vascular stability Angiopoietin-1 Angiopoietin-2 Animals Apoptosis Blood Vessels Cell Proliferation Cholesterol Side-Chain Cleavage Enzyme Corpus Luteum Female Fertility Agents, Female Gonadal Steroid Hormones Gonadotropins, Equine Leuprolide Ovarian Hyperstimulation Syndrome Ovary Phosphoproteins Rats Rats, Sprague-Dawley Receptor, TIE-2 Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-2 Irusta, Griselda Abramovich, Dalhia Nurit Tesone, Marta Parborell, M.Fernanda A. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
topic_facet |
Angiogenesis GnRH-I agonist Luteolysis OHSS Ovary alpha smooth muscle actin angiopoietin 1 angiopoietin 2 angiopoietin receptor cholesterol monooxygenase (side chain cleaving) chorionic gonadotropin cycline estradiol leuprorelin progesterone seric gonadotropin steroidogenic acute regulatory protein vasculotropin vasculotropin receptor 2 angiogenesis animal cell animal experiment animal model animal tissue apoptosis article blood vessel parameters cell proliferation controlled study corpus luteum down regulation drug efficacy drug mechanism estradiol blood level female gonadotropin blood level histopathology in vivo study luteal cell nonhuman ovary development ovary hyperstimulation peritoneal fluid level priority journal progesterone blood level protein analysis protein expression protein localization rat steroidogenesis vascular endothelium vascular stability Angiopoietin-1 Angiopoietin-2 Animals Apoptosis Blood Vessels Cell Proliferation Cholesterol Side-Chain Cleavage Enzyme Corpus Luteum Female Fertility Agents, Female Gonadal Steroid Hormones Gonadotropins, Equine Leuprolide Ovarian Hyperstimulation Syndrome Ovary Phosphoproteins Rats Rats, Sprague-Dawley Receptor, TIE-2 Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-2 |
description |
Ovarian hyperstimulation syndrome (OHSS) is a complication of ovarian stimulation with gonadotropins followed by the administration of human chorionic gonadotropin (hCG) to trigger the final steps of oocyte maturation. Gonadotropin-releasing hormone (GnRH) analogs are thought to be effective in preventing this complication and a clinical trial has found a lower incidence of OHSS in patients treated with these molecules. Our aim was to analyze the in vivo effect of a GnRH-I agonist on corpus luteum development and regression, ANGPT-1, ANGPT-2 and Tie-2 protein expression and luteal blood vessel stabilization, the expression of the steroidogenic acute regulatory protein (StAR) and the cytochrome P450 side-chain cleavage enzyme (P450scc) and cell proliferation, in ovaries from an OHSS rat model. To this end immature female Sprague-Dawley rats were hyperstimulated and treated with a GnRH-I agonist from the start of pregnant mare serum gonadotropin (PMSG) administration until the day of hCG injection for 5 consecutive days. Blood and tissue samples were collected 48. h after hCG injection. Vascular endothelial growth factor VEGF levels were evaluated in the peritoneal fluid by ELISA. Serum progesterone and estradiol were measured by RIA. Histological features of sectioned ovaries were assessed in hematoxylin and eosin (H&E) stained slides. Luteal blood vessel stability, cell proliferation and apoptosis were assessed by immunohistochemistry for SMCA, PCNA, and TUNEL, respectively. P450scc, StAR, FLK-1, ANGPT-1, ANGPT-2, Tie-2 and PCNA protein levels were evaluated by Western blot from dissected corpora lutea (CL). The treatment with the GnRH-I agonist significantly decreased serum progesterone and estradiol levels as well as P450scc and StAR protein expression in the untreated OHSS group. In addition, the agonist significantly decreased the number of CL in the OHSS group, as compared with the untreated OHSS group. In the OHSS group, the area of periendothelial cells in the CL was larger than that of the control group. However, the treatment with the GnRH-I agonist significantly reduced the area of periendothelial cells in the CL in the OHSS group. The luteal levels of ANGPT-1 and its receptor Tie-2 significantly increased in the OHSS group when compared with the control group. Conversely, the administration of the GnRH-I agonist significantly decreased the levels of these factors in the CL from the OHSS group, as compared with the untreated OHSS group. In addition, the treatment with the GnRH-I agonist reduced the diameter of CL and decreased CL cell proliferation as compared with that observed in the untreated OHSS group. Finally, the GnRH-I agonist increased apoptosis in the CL from the OHSS group. In conclusion, these results show that GnRH-I agonist exerts diverse actions on the CL from a rat OHSS model. The decrease in P450scc, StAR, ANGPT-1 and Tie-2 expression, blood vessel stability and luteal proliferation leads to CL regression in the ovaries from OHSS rats. Moreover, our results suggest that the downregulation of ANGPT-1 and its receptor is a possible mechanism whereby GnRH-I agonists could prevent early OHSS. © 2011 Elsevier Ireland Ltd. |
author |
Irusta, Griselda Abramovich, Dalhia Nurit Tesone, Marta Parborell, M.Fernanda A. |
author_facet |
Irusta, Griselda Abramovich, Dalhia Nurit Tesone, Marta Parborell, M.Fernanda A. |
author_sort |
Irusta, Griselda |
title |
Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
title_short |
Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
title_full |
Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
title_fullStr |
Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
title_full_unstemmed |
Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
title_sort |
administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome |
publishDate |
2011 |
url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03037207_v335_n2_p116_Scotti http://hdl.handle.net/20.500.12110/paper_03037207_v335_n2_p116_Scotti |
work_keys_str_mv |
AT irustagriselda administrationofagonadotropinreleasinghormoneagonistaffectscorpusluteumvascularstabilityanddevelopmentandinduceslutealapoptosisinaratmodelofovarianhyperstimulationsyndrome AT abramovichdalhianurit administrationofagonadotropinreleasinghormoneagonistaffectscorpusluteumvascularstabilityanddevelopmentandinduceslutealapoptosisinaratmodelofovarianhyperstimulationsyndrome AT tesonemarta administrationofagonadotropinreleasinghormoneagonistaffectscorpusluteumvascularstabilityanddevelopmentandinduceslutealapoptosisinaratmodelofovarianhyperstimulationsyndrome AT parborellmfernandaa administrationofagonadotropinreleasinghormoneagonistaffectscorpusluteumvascularstabilityanddevelopmentandinduceslutealapoptosisinaratmodelofovarianhyperstimulationsyndrome |
_version_ |
1768543083589271552 |
spelling |
paper:paper_03037207_v335_n2_p116_Scotti2023-06-08T15:29:08Z Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome Irusta, Griselda Abramovich, Dalhia Nurit Tesone, Marta Parborell, M.Fernanda A. Angiogenesis GnRH-I agonist Luteolysis OHSS Ovary alpha smooth muscle actin angiopoietin 1 angiopoietin 2 angiopoietin receptor cholesterol monooxygenase (side chain cleaving) chorionic gonadotropin cycline estradiol leuprorelin progesterone seric gonadotropin steroidogenic acute regulatory protein vasculotropin vasculotropin receptor 2 angiogenesis animal cell animal experiment animal model animal tissue apoptosis article blood vessel parameters cell proliferation controlled study corpus luteum down regulation drug efficacy drug mechanism estradiol blood level female gonadotropin blood level histopathology in vivo study luteal cell nonhuman ovary development ovary hyperstimulation peritoneal fluid level priority journal progesterone blood level protein analysis protein expression protein localization rat steroidogenesis vascular endothelium vascular stability Angiopoietin-1 Angiopoietin-2 Animals Apoptosis Blood Vessels Cell Proliferation Cholesterol Side-Chain Cleavage Enzyme Corpus Luteum Female Fertility Agents, Female Gonadal Steroid Hormones Gonadotropins, Equine Leuprolide Ovarian Hyperstimulation Syndrome Ovary Phosphoproteins Rats Rats, Sprague-Dawley Receptor, TIE-2 Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-2 Ovarian hyperstimulation syndrome (OHSS) is a complication of ovarian stimulation with gonadotropins followed by the administration of human chorionic gonadotropin (hCG) to trigger the final steps of oocyte maturation. Gonadotropin-releasing hormone (GnRH) analogs are thought to be effective in preventing this complication and a clinical trial has found a lower incidence of OHSS in patients treated with these molecules. Our aim was to analyze the in vivo effect of a GnRH-I agonist on corpus luteum development and regression, ANGPT-1, ANGPT-2 and Tie-2 protein expression and luteal blood vessel stabilization, the expression of the steroidogenic acute regulatory protein (StAR) and the cytochrome P450 side-chain cleavage enzyme (P450scc) and cell proliferation, in ovaries from an OHSS rat model. To this end immature female Sprague-Dawley rats were hyperstimulated and treated with a GnRH-I agonist from the start of pregnant mare serum gonadotropin (PMSG) administration until the day of hCG injection for 5 consecutive days. Blood and tissue samples were collected 48. h after hCG injection. Vascular endothelial growth factor VEGF levels were evaluated in the peritoneal fluid by ELISA. Serum progesterone and estradiol were measured by RIA. Histological features of sectioned ovaries were assessed in hematoxylin and eosin (H&E) stained slides. Luteal blood vessel stability, cell proliferation and apoptosis were assessed by immunohistochemistry for SMCA, PCNA, and TUNEL, respectively. P450scc, StAR, FLK-1, ANGPT-1, ANGPT-2, Tie-2 and PCNA protein levels were evaluated by Western blot from dissected corpora lutea (CL). The treatment with the GnRH-I agonist significantly decreased serum progesterone and estradiol levels as well as P450scc and StAR protein expression in the untreated OHSS group. In addition, the agonist significantly decreased the number of CL in the OHSS group, as compared with the untreated OHSS group. In the OHSS group, the area of periendothelial cells in the CL was larger than that of the control group. However, the treatment with the GnRH-I agonist significantly reduced the area of periendothelial cells in the CL in the OHSS group. The luteal levels of ANGPT-1 and its receptor Tie-2 significantly increased in the OHSS group when compared with the control group. Conversely, the administration of the GnRH-I agonist significantly decreased the levels of these factors in the CL from the OHSS group, as compared with the untreated OHSS group. In addition, the treatment with the GnRH-I agonist reduced the diameter of CL and decreased CL cell proliferation as compared with that observed in the untreated OHSS group. Finally, the GnRH-I agonist increased apoptosis in the CL from the OHSS group. In conclusion, these results show that GnRH-I agonist exerts diverse actions on the CL from a rat OHSS model. The decrease in P450scc, StAR, ANGPT-1 and Tie-2 expression, blood vessel stability and luteal proliferation leads to CL regression in the ovaries from OHSS rats. Moreover, our results suggest that the downregulation of ANGPT-1 and its receptor is a possible mechanism whereby GnRH-I agonists could prevent early OHSS. © 2011 Elsevier Ireland Ltd. Fil:Irusta, G. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Abramovich, D. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Tesone, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Parborell, F. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2011 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03037207_v335_n2_p116_Scotti http://hdl.handle.net/20.500.12110/paper_03037207_v335_n2_p116_Scotti |